2018
DOI: 10.1016/j.mtcomm.2018.09.011
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: A B S T R A C TRheumatoid arthritis (RA) is the most common complex multifactorial joint related autoimmune inflammatory disease with unknown etiology accomplished with increased cardiovascular risks. RA is characterized by the clinical findings of synovial inflammation, autoantibody production, and cartilage/bone destruction, cardiovascular, pulmonary and skeletal disorders. Pro-inflammatory cytokines such as IL-1, IL-6, IL-8, and IL-10 were responsible for the induction of inflammation in RA patients. Drawba… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
27
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 40 publications
(27 citation statements)
references
References 93 publications
0
27
0
Order By: Relevance
“…[13] Although the medication of IL-1 receptor antagonist (IL1ra) has been approved by the US Food and Drug Administration (FDA), it is reported that the protein IL1ra therapeutic and derivatives show short half-life from a few minutes to 1-4 h. [14][15][16] It therefore requires frequent dosage administration as high as 1-2 times per day, which greatly decreases patient compliance and results in higher expenses. [13,17] Thus, there is still largely unmet clinical need to prolong systemic circulation of the medication and increase bioavailability to realize long-acting effect and increase the drug regimen.Nanoparticle-based therapy has attracted tremendous attention in arthritis and related-biomedical communities over past few years. [18][19][20][21][22][23] Owing to its effective approach which provides protection of encapsulated payloads from degradation in the circulation, the formulation of drugs into nanoparticles has many potential advantages over conventional modalities especially in enhanced bioavailability and improved efficacy.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…[13] Although the medication of IL-1 receptor antagonist (IL1ra) has been approved by the US Food and Drug Administration (FDA), it is reported that the protein IL1ra therapeutic and derivatives show short half-life from a few minutes to 1-4 h. [14][15][16] It therefore requires frequent dosage administration as high as 1-2 times per day, which greatly decreases patient compliance and results in higher expenses. [13,17] Thus, there is still largely unmet clinical need to prolong systemic circulation of the medication and increase bioavailability to realize long-acting effect and increase the drug regimen.Nanoparticle-based therapy has attracted tremendous attention in arthritis and related-biomedical communities over past few years. [18][19][20][21][22][23] Owing to its effective approach which provides protection of encapsulated payloads from degradation in the circulation, the formulation of drugs into nanoparticles has many potential advantages over conventional modalities especially in enhanced bioavailability and improved efficacy.…”
mentioning
confidence: 99%
“…[13] Although the medication of IL-1 receptor antagonist (IL1ra) has been approved by the US Food and Drug Administration (FDA), it is reported that the protein IL1ra therapeutic and derivatives show short half-life from a few minutes to 1-4 h. [14][15][16] It therefore requires frequent dosage administration as high as 1-2 times per day, which greatly decreases patient compliance and results in higher expenses. [13,17] Thus, there is still largely unmet clinical need to prolong systemic circulation of the medication and increase bioavailability to realize long-acting effect and increase the drug regimen.…”
mentioning
confidence: 99%
“…Silver NPs (Ag NPs) have been reported for their anti-inflammatory activities by limiting the production of proinflammatory cytokines such as TNF-α and IL-6 and have been beneficial in RA patients [ 146 ]. Ag NPs can also reduce the amount of vascular endothelial growth factor (VEGF), a factor produced by epithelial cells that increases antigen sensitivity, exhibits a major function in physiological abnormalities, causes plasma proteins to leak into the extracellular space, leads to a thickening of the airway wall, and increases the T helper type-2 (TH2) cell-mediated inflammation (IL-9, IL-4, IL-5, and IL-13) [ 147 ].…”
Section: Nanomaterials For the Treatment Of Inflammatory Arthritismentioning
confidence: 99%
“…SLNs are novel and interesting pharmaceutical drug delivery platforms with a diameter of 120–200 nm that are extensively used for managed drug delivery, combining the advantages of polymeric NPs and oil-in-water emulsions [ 146 ].…”
Section: Nanomaterials For the Treatment Of Inflammatory Arthritismentioning
confidence: 99%
“…Indeed, there has been extensive research using these compounds for delivering drugs for treating diabetes, pain, infections, and cancer, some with the ability to target specific cells and some capable of producing particles with size ranging from 1 nm up to 1000 nm [ 143 ]. When it comes to RA therapy, many researchers were able to employ these exciting properties of the marine-derived compounds for modifying pharmacokinetics of other drugs to control inflammation [ 144 ]. A platform of alginate beads has successfully delayed the release of Prednisolone in rats [ 145 ].…”
Section: Advantages and Applications Of Various Marine-derived Commentioning
confidence: 99%